Chemotherapy Efficacy Lower Than Expected in Ki67-expressing Tumors

Share this content:
The efficacy of neoadjuvant chemotherapy was lower than expected for patients with ER-positive primary breast cancer.
The efficacy of neoadjuvant chemotherapy was lower than expected for patients with ER-positive primary breast cancer.

The efficacy of neoadjuvant chemotherapy was lower than expected for patients with estrogen receptor (ER)-positive primary breast cancer exhibiting high levels of Ki67 after 2 to 4 weeks of neoadjuvant aromatase inhibitor therapy (AI), according to a study published in the Journal of Clinical Oncology.1

To evaluate Ki67 as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor therapy of breast cancer, researchers assessed the pathologic complete response rate of women with ER-positive primary breast cancer triaged to chemotherapy when the Ki67 level was greater than 10% after AI treatment.

For the open-label, phase 3 American College of Surgeons Oncology Group (ACOSOG) Z1031B trial (ClinicalTrials.gov Identifier: NCT00265759), researchers enrolled postmenopausal women with stage II or III ER-positive breast cancer and randomly assigned them to receive neoadjuvant AI therapy with anastrozole, exemestane, or letrozole.

If Ki67 level was greater than 10% after 2 to 4 weeks of an AI, patients were switched to neoadjuvant chemotherapy. Investigators defined the efficacy threshold as a pathologic complete response rate of greater than 20%.

Only 5.7% (95% CI, 0.7-19.1) of the 35 patients who were switched to neoadjuvant chemotherapy achieved a pathologic complete response.

Researchers also assessed whether time to recurrence differed by Ki67-based Preoperative Endocrine Prognostic Index (PEPI) score. Patients with T1 or T2, N0, Ki67 less than 2.7%, and an Allred score greater than 2 had a PEPI score of 0.

Median follow-up was 5.5 years; patients with a PEPI score of 0 had a 73% lower risk of recurrence compared with those with a PEPI score greater than 0 (hazard ratio, 0.27; 95% CI, 0.092-0.764; P = .014). Nearly 4% of the 109 patients with a PEPI score of 0 relapsed vs 14.4% of the 341 patients with a PEPI score greater than 0.

These findings support the investigation of adjuvant endocrine monotherapy in this subpopulation.

RELATED: Diarrhea Manageable With Pertuzumab Treatment for Breast Cancer

Researchers are studying both the Ki67 proliferation index and the PEPI score approach in the phase 3 ALTERNATE study (ClinicalTrials.gov Identifier: NCT01953588), which is comparing the efficacy of neoadjuvant fulvestrant with the combination of fulvestrant plus anastrozole among postmenopausal women with stage II or III ER-positive breast cancer.

Reference

  1. Ellis MJ, Suman VJ, Hoog J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: Results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Jan 3. doi: 10.1200/JCO.2016.69.4406 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters